• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种用于宿主-病毒结合筛选的多参数高通量平台。

A Multiparametric and High-Throughput Platform for Host-Virus Binding Screens.

机构信息

Science for Life Laboratory, Department of Women's and Children's Health, Karolinska Institutet, 17165 Solna, Sweden.

Science for Life Laboratory, Division of Genome Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, 17165 Stockholm, Sweden.

出版信息

Nano Lett. 2023 May 10;23(9):3701-3707. doi: 10.1021/acs.nanolett.2c04884. Epub 2023 Mar 9.

DOI:10.1021/acs.nanolett.2c04884
PMID:36892970
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10176574/
Abstract

Speed is key during infectious disease outbreaks. It is essential, for example, to identify critical host binding factors to pathogens as fast as possible. The complexity of host plasma membrane is often a limiting factor hindering fast and accurate determination of host binding factors as well as high-throughput screening for neutralizing antimicrobial drug targets. Here, we describe a multiparametric and high-throughput platform tackling this bottleneck and enabling fast screens for host binding factors as well as new antiviral drug targets. The sensitivity and robustness of our platform were validated by blocking SARS-CoV-2 particles with nanobodies and IgGs from human serum samples.

摘要

速度是传染病爆发时的关键。例如,尽快识别病原体的关键宿主结合因子至关重要。宿主质膜的复杂性通常是一个限制因素,阻碍了宿主结合因子的快速准确确定以及中和抗菌药物靶点的高通量筛选。在这里,我们描述了一个多参数和高通量的平台,解决了这个瓶颈,使宿主结合因子的快速筛选以及新的抗病毒药物靶点成为可能。我们的平台的灵敏度和稳健性通过用来自人血清样本的纳米抗体和 IgG 阻断 SARS-CoV-2 颗粒得到了验证。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3c4/10176574/b730986dbfcc/nl2c04884_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3c4/10176574/64a2c613f948/nl2c04884_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3c4/10176574/28d3d319ea1b/nl2c04884_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3c4/10176574/bf9d8f71779e/nl2c04884_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3c4/10176574/b730986dbfcc/nl2c04884_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3c4/10176574/64a2c613f948/nl2c04884_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3c4/10176574/28d3d319ea1b/nl2c04884_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3c4/10176574/bf9d8f71779e/nl2c04884_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3c4/10176574/b730986dbfcc/nl2c04884_0004.jpg

相似文献

1
A Multiparametric and High-Throughput Platform for Host-Virus Binding Screens.一种用于宿主-病毒结合筛选的多参数高通量平台。
Nano Lett. 2023 May 10;23(9):3701-3707. doi: 10.1021/acs.nanolett.2c04884. Epub 2023 Mar 9.
2
The spike-ACE2 binding assay: An in vitro platform for evaluating vaccination efficacy and for screening SARS-CoV-2 inhibitors and neutralizing antibodies.刺突蛋白-ACE2 结合分析:评估疫苗效力和筛选 SARS-CoV-2 抑制剂及中和抗体的体外平台。
J Immunol Methods. 2022 Apr;503:113244. doi: 10.1016/j.jim.2022.113244. Epub 2022 Feb 23.
3
Identification of SARS-CoV-2 Cell Entry Inhibitors by Drug Repurposing Using Structure-Based Virtual Screening Approach.基于结构的虚拟筛选方法通过药物再利用鉴定 SARS-CoV-2 细胞进入抑制剂。
Front Immunol. 2020 Jul 10;11:1664. doi: 10.3389/fimmu.2020.01664. eCollection 2020.
4
SARS-CoV-2 attachment to host cells is possibly mediated via RGD-integrin interaction in a calcium-dependent manner and suggests pulmonary EDTA chelation therapy as a novel treatment for COVID 19.SARS-CoV-2 可能通过依赖钙的 RGD-整联蛋白相互作用与宿主细胞结合,这提示肺部 EDTA 螯合疗法可能是 COVID-19 的一种新的治疗方法。
Immunobiology. 2021 Jan;226(1):152021. doi: 10.1016/j.imbio.2020.152021. Epub 2020 Nov 5.
5
Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2-ACE2 Receptor Interactions.多学科方法鉴定与人 ACE2 或 SARS-CoV-2 刺突蛋白结合的化合物,作为阻断 SARS-CoV-2-ACE2 受体相互作用的候选药物。
mBio. 2021 Mar 30;12(2):e03681-20. doi: 10.1128/mBio.03681-20.
6
Antiviral Disaccharide Lead Compounds against SARS-CoV-2 through Computer-Aided High-Throughput Screen.通过计算机辅助高通量筛选发现针对 SARS-CoV-2 的抗病毒二糖先导化合物。
Chembiochem. 2022 Dec 16;23(24):e202200461. doi: 10.1002/cbic.202200461. Epub 2022 Nov 15.
7
Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.竞争性 SARS-CoV-2 血清学研究表明,大多数针对刺突受体结合域的抗体竞争与 ACE2 结合。
mSphere. 2020 Sep 16;5(5):e00802-20. doi: 10.1128/mSphere.00802-20.
8
Identification of SARS-CoV-2 Receptor Binding Inhibitors by In Vitro Screening of Drug Libraries.通过药物文库的体外筛选鉴定 SARS-CoV-2 受体结合抑制剂。
Molecules. 2021 May 27;26(11):3213. doi: 10.3390/molecules26113213.
9
V367F Mutation in SARS-CoV-2 Spike RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity through Increased Human ACE2 Receptor Binding Affinity.SARS-CoV-2 刺突 RBD 中的 V367F 突变增强了与人类 ACE2 受体的结合亲和力,从而提高了病毒的感染性。
J Virol. 2021 Jul 26;95(16):e0061721. doi: 10.1128/JVI.00617-21.
10
Exploring the Role of Glycans in the Interaction of SARS-CoV-2 RBD and Human Receptor ACE2.探讨聚糖在 SARS-CoV-2 RBD 与人受体 ACE2 相互作用中的作用。
Viruses. 2021 May 17;13(5):927. doi: 10.3390/v13050927.

引用本文的文献

1
Ca1.3 channel clusters characterized by live-cell and isolated plasma membrane nanoscopy.活细胞和分离质膜纳米scopy 表征的 Ca1.3 通道簇。
Commun Biol. 2024 May 23;7(1):620. doi: 10.1038/s42003-024-06313-3.

本文引用的文献

1
Supported Natural Membranes on Microspheres for Protein-Protein Interaction Studies.用于蛋白质-蛋白质相互作用研究的微球负载天然膜
ACS Appl Mater Interfaces. 2022 Nov 9;14(44):49532-49541. doi: 10.1021/acsami.2c13095. Epub 2022 Oct 28.
2
Systematic design of cell membrane coating to improve tumor targeting of nanoparticles.系统设计细胞膜涂层以提高纳米颗粒的肿瘤靶向性。
Nat Commun. 2022 Oct 19;13(1):6181. doi: 10.1038/s41467-022-33889-3.
3
T-cell trans-synaptic vesicles are distinct and carry greater effector content than constitutive extracellular vesicles.
T 细胞跨突触囊泡是独特的,比组成型细胞外囊泡携带更多的效应物内容。
Nat Commun. 2022 Jun 16;13(1):3460. doi: 10.1038/s41467-022-31160-3.
4
A bispecific monomeric nanobody induces spike trimer dimers and neutralizes SARS-CoV-2 in vivo.一种双特异性单体纳米抗体可诱导刺突三聚体二聚化并在体内中和新冠病毒。
Nat Commun. 2022 Jan 10;13(1):155. doi: 10.1038/s41467-021-27610-z.
5
Sialic acid-containing glycolipids mediate binding and viral entry of SARS-CoV-2.含唾液酸的糖脂介导 SARS-CoV-2 的结合和病毒进入。
Nat Chem Biol. 2022 Jan;18(1):81-90. doi: 10.1038/s41589-021-00924-1. Epub 2021 Nov 9.
6
Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum.恢复期患者血清和 BNT162b2 疫苗接种血清对 SARS-CoV-2 变异株的中和作用。
Nat Commun. 2021 Aug 26;12(1):5135. doi: 10.1038/s41467-021-25479-6.
7
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.中和抗体水平高度预测对有症状的 SARS-CoV-2 感染的免疫保护作用。
Nat Med. 2021 Jul;27(7):1205-1211. doi: 10.1038/s41591-021-01377-8. Epub 2021 May 17.
8
How Does Liquid-Liquid Phase Separation in Model Membranes Reflect Cell Membrane Heterogeneity?模型膜中的液-液相分离如何反映细胞膜的异质性?
Membranes (Basel). 2021 Apr 28;11(5):323. doi: 10.3390/membranes11050323.
9
Diagnostics for SARS-CoV-2 infections.用于 SARS-CoV-2 感染的诊断方法。
Nat Mater. 2021 May;20(5):593-605. doi: 10.1038/s41563-020-00906-z. Epub 2021 Feb 15.
10
Flow cytometry multiplexed method for the detection of neutralizing human antibodies to the native SARS-CoV-2 spike protein.用于检测针对天然 SARS-CoV-2 刺突蛋白的中和性人抗体的流式细胞术多重检测方法。
EMBO Mol Med. 2021 Mar 5;13(3):e13549. doi: 10.15252/emmm.202013549. Epub 2021 Feb 17.